In the BioHarmony Drug Report Database

"Preview" Icon

Capmatinib

Tabrecta, Capmatinib (capmatinib) is a small molecule pharmaceutical. Capmatinib was first approved as Tabrecta on 2008-06-10. It is used to treat non-small-cell lung carcinoma in the USA. It has been approved in Europe to treat breast neoplasms. The pharmaceutical is active against hepatocyte growth factor receptor. Tabrecta’s patents are valid until 2035-07-22 (FDA).

 

Trade Name

 

Capmatinib
 

Common Name

 

capmatinib
 

ChEMBL ID

 

CHEMBL3188267
 

Indication

 

breast neoplasms, non-small-cell lung carcinoma
 

Drug Class

 

Tyrosine kinase inhibitors

Image (chem structure or protein)

Capmatinib structure rendering